Sporadic inclusion body myositis (sIBM) is a chronic and progressive inflammatory myopathy that is commonest in the population aged >50 years. Asymmetric muscle weakness and wasting of the quadriceps, and finger and wrist flexor muscles are characteristic of sIBM. Histological findings for sIBM are characterized by a combination of inflammatory and myodegenerative pathologies. The pathogenesis of sIBM is not yet fully understood, and serum markers have not been identified for diagnosis of the disease or assessment of therapeutic efficacy. Recently, autoantibodies against cytosolic 5 0 -nucleotidase 1A have been identified in plasma and serum samples from patients with sIBM. Various methods with clinical utility have been established to detect anti-cN1A autoantibodies for the diagnosis of sIBM. Importantly, the autoantibodies might have direct roles in the development of the disease by causing dysfunction in proteasomal and lysosomal degradation. Future studies should be carried out to elucidate the molecular mechanisms by which the sarcoplasmic autoantigen is recognized and involved in the degeneration of myofibers. Additional research is essential to provide a better understanding of the relationship between the inflammatory and degenerative processes of sIBM.
Introduction
Sporadic inclusion body myositis (sIBM), a progressive, chronic inflammatory myopathy, is commonest in adults aged >50 years.
1,2 Chou first described a 66-year-old man with chronically progressive myositis whose muscle biopsy showed distinctive intranuclear and cytoplasmic filamentous inclusions and vacuoles. 3 Yunis and Samaha later introduced the term, inclusion body myositis, in 1971; 4 then Mendell et al. 5 identified the presence of amyloid-like filaments in the myofibers in sIBM in 1991.
Patients with sIBM usually present with asymmetric muscle weakness and wasting of the quadriceps, and/or finger and wrist flexor muscles. Histological findings for the disease are characterized by degenerative changes with rimmed vacuoles and inflammatory cell infiltration. The slow progression and clinical heterogeneity of the disease can lead to delayed diagnosis. Although sIBM belongs to the category of inflammatory myopathies, which includes dermatomyositis, polymyositis and immunemediated necrotizing myopathy, it is refractory to common immunomodulatory therapies. Therefore, diagnostic markers for sIBM have long been sought.
Recently, there have been advances in the search for disease biomarkers, such as the identification of autoantibodies against cytosolic 5 0 -nucleotidase 1A (NT5C1A or cN1A). 6, 7 The autoantibodies are expected to help resolve if sIBM is a primary autoimmune disease of the muscle or a degenerative myopathy with subsequent inflammatory responses. In this review, we focus on the utility of anti-cN1A autoantibodies in the diagnosis and understanding of the pathogenesis of sIBM.
prevalence has been reported as 10.7, 14.9, 4.9, 33, and 1.1 cases per million in the USA, Western Australia, the Netherlands, Norway and Turkey, respectively. [8] [9] [10] [11] [12] In Japan, the number of patients diagnosed with sIBM has been estimated as 1000-1500, suggesting that the prevalence of sIBM in Japan was 9.83 cases per million in 2003. 13 A retrospective survey showed a drastic increase in the prevalence of sIBM in Japan since 2002, probably due to the increased life expectancy in Japan, or the rapid change in dietary habits from a traditional style to a Westernized diet after World War II.
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Clinical characteristics
Asymmetric muscle weakness and wasting of the quadriceps, and the finger and wrist flexor muscles are characteristic of sIBM. The disease usually manifests after the age of 50 years, but the symptoms can start around the age of 30 years. 1 Typically, patients with sIBM notice severe weakness and atrophy of the quadriceps muscles ( Fig. 1) , resulting in difficulty climbing up and down stairs, rising from the floor, squatting or kneeling, and, consequently, frequent falls. 2 Among the forearm muscles, the flexors, including the flexor digitorum profundus (FDP) muscle, are most severely affected ( Fig. 1) , leading to difficulty in gripping, removing bottle caps and using handheld tools or household implements. 2 On progression of the disease, other muscle groups can be involved to varying degrees. Although mild weakness of the facial muscles is possible, the extraocular muscles are spared even in the advanced stages. Dysphagia, a relatively frequent symptom, is reported in two-thirds of the patients at some stage of the disease. 15 Cognitive impairment is not associated with the disease in most cases.
In a cross-sectional and self-reporting survey, the mean age of the 916 participants with sIBM was 70.4 years, the male-to-female ratio was 2:1 and the mean time from first symptoms to diagnosis was 4.7 years. 16 Just half of the patients were initially diagnosed with sIBM. Ambulation and daily activity were negatively associated with age and disease duration, and positively associated with participation in exercise. 16 A cross-sectional analysis of Japanese sIBM patients showed the length of time from the onset of disease to milestone symptoms: inability to stand independently, 4.6 years; becoming wheelchair-bound, 7.3 years; becoming electrical wheelchair-bound, 13.7 years; inability to open a plastic bottle, 6.6 years; and inability to wash their own face, 7.2 years. 14 Of note, a considerable number of patients expressed psychological, mental and financial anxiety due to the aged profile of sIBM patients. 14 The commonest cause of death in patients with sIBM is pneumonia arising from dysphagia. 17 A 12-year follow-up study of Dutch patients with sIBM showed that life expectancy was not shortened for patients with sIBM, compared with the general Dutch population. 18 However, respiratory disorder, especially pneumonia, was a frequent cause of death in sIBM patients, compared with an age-matched general Dutch population (aged 80-85 years). 18 A study of French and British sIBM patients showed that 75% of patients had significant difficulty walking, and 37% used a wheelchair during a median 14-year follow up. 19 The study showed that the risk of death was only influenced by older age at the time of the onset of symptoms, although life expectancy was generally not affected by sIBM. 19 
Diagnosis
Electrophysiology
Needle electromyography can show a typical myopathic pattern in cases of sIBM, as well as neurogenic changes, including high amplitude and long duration motor unit potentials. These neurogenic changes in sIBM might lead to a misdiagnosis of amyotrophic lateral sclerosis. 20 One study recommended examination of the FDP muscle to reduce the possibility of misdiagnosing sIBM as amyotrophic lateral sclerosis. 21 
Radiology
Magnetic resonance imaging carried out in a large number of patients with sIBM showed a distinct pattern of muscle involvement, such as frequent fatty infiltration in the FDP, the quadriceps (except the rectus femoris), the adductor muscles and the medial region of the gastrocnemius muscle. 22 Recent studies showed the differences in the echo intensities between the FDP and flexor carpi ulnaris, or between the gastrocnemius and soleus of patients with sIBM, suggesting a possible diagnostic indicator of sIBM.
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Histology
Muscle biopsy is necessary for definitive diagnosis of sIBM. Muscle histology in sIBM is characterized by a combination of inflammatory and myodegenerative pathologies. 25 Inflammatory changes include endomysial cellularity, focal invasion and upregulation of immune markers (Fig. 2a-c) . Myodegenerative changes include protein aggregates, rimmed vacuoles ( Fig. 2d ) and mitochondrial features. Abnormal sarcoplasmic aggregation, including that of amyloid b (Ab) and its oligomers, and that of phosphorylated tau in the form of paired helical filaments, has been observed in muscle fibers from sIBM patients. 26, 27 TAR DNA-binding protein of 43 kDa (TDP-43), an evolutionarily conserved, ubiquitously expressed, multi-functional DNA/RNA-binding protein, has been shown to accumulate in degenerative myofibers in sIBM. Sarcoplasmic accumulation of TDP-43 is observed in 25-32.5% of myofibers in sIBM patients, whereas other indicators, such as rimmed vacuoles, congophilic materials, SMI-31 immunoreactivity and Ab immunoreactivity, are detected less frequently. [27] [28] [29] [30] [31] Recent investigations have shown that p62/SQSTM1, a multi-functional adaptor protein that balances apoptotic cell death and cell survival, accumulates more frequently within degenerative myofibers of sIBM, compared with the other indicators. 31, 32 These pathological observations might provide not only a diagnostic index, but a clue to understanding the pathogenesis of sIBM. Serum markers: anti-cytosolic 5 0 -nucleotidase 1A autoantibodies Serum levels of creatine kinase are normal or moderately elevated, by <10-fold the upper limit of the normal range, in sIBM patients. 2 Most cases are negative for myositis-specific and myositis-associated autoantibodies, such as anti-Jo-1 antibody. The development of serum markers to facilitate earlier diagnosis of the disease and assessment of therapeutic efficacy has been an urgent issue. Salajegheh et al. 33 first detected autoantibodies in the plasma and serum samples of patients with sIBM in 2011; then, two groups identified the target antigen of the autoantibodies as cN1A in 2013. 6, 7 Larman et al., utilizing a dot-blot assay, reported that the moderately reactive anti-cN1A autoantibodies were 70% sensitive and 92% specific, and that highly reactive antibodies were 34% sensitive and 98% specific, for the diagnosis of sIBM. 6 Furthermore, Greenberg reported that combination assays for all autoantibody isotypes (immunoglobulin [Ig]G, IgM and IgA) improved the diagnostic sensitivity for sIBM up to 76%. 34 Since the identification of the presence of anti-cN1A autoantibodies in sIBM, different methodologies for their detection have emerged, such as immunoprecipitation, 6, 7 immunoblotting with human skeletal muscle extracts 6, 7, 33 or lysates of cN1A-expressing human embryonic kidney 293 cells, 35, 36 and enzyme-linked immunosorbent assays with recombinant full-length cN1A protein 34, 36 or synthetic peptides derived from cN1A. 37 In Table 1, we summarized the frequencies of seropositivity for anti-cN1A autoantibodies in various diseases using different methodologies. The specificities and sensitivities vary among the methodologies. Although anti-cN1A autoantibodies were found in patients with several different autoimmune diseases, including systemic lupus erythematosus and Sj€ ogren's syndrome, a considerable proportion of sIBM patients showed seropositivity for anti-cN1A autoantibodies, suggesting clinical utility for the autoantibodies. Recent studies showed that endoplasmic reticulum stress is activated in the myofibers of patients with inflammatory myopathies including polymyositis and dermatomyositis, suggesting its contribution to the pathogenesis of myositis. 38, 39 As cN1A is an aggregation-prone protein, the aggregated protein might be presented as an autoantigen under pathological conditions, leading to production of the autoantibodies. Our group established a novel cellbased assay for the detection of the autoantibodies, which had apparently equivalent sensitivity and better specificity for the diagnosis of sIBM, compared with the previously described methods. 40 In order to establish the usefulness of measuring anti-cN1A autoantibodies to facilitate a more accurate diagnosis of sIBM, additional research is required to standardize antibody detection methods, along with consideration of the epitopes recognized by the antibodies and the immunoglobulin isotypes.
Diagnostic criteria
When Bohan and Peter established diagnostic criteria for polymyositis and dermatomyositis in 1975, sIBM Table 1 The percentage of anti-cN1A autoantibody-seropositive patients with various diseases as detected by alternative methodologies Salajegheh, 2011 33 Pluk, 2013 7 Larman, 2013 6 Lloyd, 2016 35 Goyal, 2016 36 Greenberg, 2014 34 Herbert, 2016 37 Our study (Tawara, 2017 40 41 Lloyd et al. 41 reviewed 24 previously proposed sIBM diagnostic categories and found that the best performing category was the European Neuromuscular Center 2013 probable, with the highest sensitivity at 84%. They also proposed "data-derived diagnostic criteria" with higher performance: (i) finger flexor or quadriceps weakness; (ii) endomysial inflammation; and (iii) either invasion of non-necrotic muscle fibers or rimmed vacuoles, with 90% sensitivity and 96% specificity. 41 Some patients wait more than 5 years to receive a diagnosis of sIBM, probably because of the difficulty in diagnosis of the disease and/or a delay in consultation; they are often misdiagnosed with polymyositis or motor neuron diseases. Muscle biopsies from inadequate regions of muscles might prevent the detection of specific histological changes in patients with sIBM. As the histological features vary according to the disease duration and the location of the muscle biopsy in sIBM, clinicians must specifically take sIBM into consideration in middle-aged and older patients with chronic progressive myopathies.
Pathogenesis in sIBM
Immunological pathomechanisms Mononuclear infiltrate of CD8 + cytotoxic T cells in or surrounding non-necrotic myofibers is a typical feature in the muscle biopsies of sIBM patients. Some of the non-necrotic myofibers express major histocompatibility class I antigen on the sarcolemma. Muscle-invading CD8 + cytotoxic T cells have cytotoxic activity and express mediators, such as perforin and granzyme A. 42 In addition, oligoclonally or polyclonally expanded T cells have been identified in the myofibers of sIBM patients. 43 A study showed that clonally expanded, muscle-infiltrating CD8 + T cells recirculate in the blood, which supports a CD8 + Tcell-mediated autoimmune pathomechanism for sIBM. 44 Recently, Greenberg et al. 45 showed that CD8 + CD57 + lymphocytes, which expand clonally in the peripheral blood and bone marrow of patients with T-cell large granular lymphocytic leukemia, can frequently be found in the blood of sIBM patients (58%). Furthermore, they found a correlation between the degree of expansion of the CD8 + CD57 + lymphocytes in the blood and the degree of invasion of these T cells into the biopsied muscle tissues, as well as the degree of the progression of muscle weakness. 45 CD8 + CD57 + T cells are believed to be highly differentiated antigen-driven effector cells that mediate severe cytotoxicity because of their high expression of adhesion molecules and their strong migratory potential. Thus, the development of aggressive, apoptosis-resistant T cells might explain why sIBM is refractory to commonly used immunosuppressants.
The presence of anti-cN1A autoantibodies also suggests an immunological pathomechanism for sIBM. With regard to the clinicopathological features of sIBM patients with anti-cN1A autoantibodies, an initial study suggested that seropositivity for the anti-cN1A autoantibodies was associated with greater motor and functional disability: sIBM patients with the autoantibodies showed more prominent bulbar, facial and respiratory symptoms. 36 In our investigation, the percentage of patients with hepatitis C virus antibodies was significantly lower, and the mean area of type 2 myofibers was significantly smaller in the anti-cN1A-positive group compared with the autoantibody-negative group. 40 A recent retrospective study of 311 sIBM patients showed that the anti-cN1A-positive patients had a higher adjusted mortality risk, lower frequency of proximal upper limb weakness at disease onset and an increased prevalence of excess cytochrome oxidase-deficient myofibers in muscle biopsy samples. 46 Thus, the observation that patients with anti-cN1A autoantibodies manifested distinct clinicopathological features might indicate the existence of a unique pathomechanism in sIBM.
The pathogenic role of anti-cN1A autoantibodies has not been fully investigated. However, we found that p62 was significantly upregulated in anti-cN1A-positive sIBM IgG-supplemented cells in an in vitro passive immunization model. 40 Similar p62-positive sarcoplasmic aggregates were observed in the myofibers of anti-cN1A-positive sIBM IgG-injected mice in an in vivo passive immunization model. 40 We also found that cN1A expression levels were reduced in the muscle tissues of patients with sIBM that is associated with anti-cN1A autoantibodies, as well as in lysates from the antibody-positive IgG-supplemented cells. These findings might help elucidate the possible pathogenic role of the antibodies in muscle degeneration, and could explain the undetermined relationship between the immunological and degenerative mechanisms.
Similar to other autoimmune diseases, a viral contribution to the etiology of sIBM has been considered. Uruha et al. 47 recently reported that a significantly higher proportion of patients with sIBM (28%) had anti-hepatitis C virus antibodies than either patients with polymyositis (4.5%) or the agematched Japanese population (3.4%), which suggests a possible pathomechanistic link between sIBM and hepatitis C virus infection. There have been several reports regarding sIBM patients with HIV-1 infection or human T-lymphotropic virus-type I (HTLV-I) infection. 48 A case report on a patient with sIBM and HTLV-I infection showed rapid progression of muscle weakness and the possible complication of hypertrophic cardiomyopathy, resulting in sudden death. 49 In an endemic area for HTLV-1 infection, the frequency of HTLV-I infection among sIBM patients was 52.3% as opposed to 27.5% and 11.6% in patients with polymyositis and the general population, respectively. 50 HTLV-I proviral loads were elevated in the peripheral blood mononuclear cells of sIBM patients with HTLV-I infection, similar to those with HTLV-I-associated myelopathy/tropical spastic paraparesis. 48 The same study showed that both HTLV-I-infected helper-inducer T cells and HTLV-I tax-specific cytotoxic T cells infiltrated the muscles of an HTLV-I-infected patient with sIBM, as happens in sIBM that occurs in the context of HIV-1 infection. 51 Of note, HIV-positive patients with myositis eventually develop features resembling sIBM, including finger and wrist flexor weakness, rimmed vacuoles on biopsy, or anti-cN1A autoantibodies. 52 Collectively, the muscle invasion of antigen-specific T-cell populations activated by chronic viral infection might drive the development of sIBM concurrent with viral infection.
Degenerative pathomechanisms
Intranuclear and cytoplasmic filamentous inclusions in sIBM were initially detected by electron microscopy or Congo red staining. Subsequently, a number of abnormal sarcoplasmic aggregations, including Ab, phosphorylated tau, TDP-43 and p62, were found in the affected myofibers of sIBM. These inclusions and sarcoplasmic aggregations, as well as rimmed vacuoles, strongly support a degenerative pathomechanism for sIBM. The protein p62 is a shuttle that transports polyubiquitinated proteins for both the proteasomal and lysosomal degradation pathways. Thus, the sarcoplasmic accumulation of p62 is likely to imply dysfunction in proteasomal and lysosomal degradation.
Animals in a transgenic model with muscle-specific overexpression of Ab precursor protein developed weakness and sIBM-like histopathological features, including intracellular accumulation of Ab, without intramuscular inflammatory infiltrates. 53, 54 Musclespecific overexpression of the heavy chain of major histocompatibility class I produced severe myopathy in immunocompetent mice on the induction of endoplasmic reticulum stress. 55 In addition, cellular TDP-43 levels are tightly regulated, and it is likely that TDP-43 aggregates lead to the disruption of TDP-43 self-regulation, resulting in pathogenesis. 56 As for the mechanism of proteasomal and autophagy dysfunctions in sIBM, an overload of substrates that should be cleared by the protein degradation systems might result in misfolded and/or ubiquitinated proteins and endoplasmic reticulum stress, leading to vacuolar myopathic changes.
The sarcoplasmic accumulation of p62 and/or TDP-43 and rimmed vacuoles are not only pathological hallmarks for sIBM, but also for hereditary inclusion body myopathies or other protein aggregate myopathies. Mutations in the valosin-containing protein gene, an adenosine triphosphatase involved in protein degradation and autophagy, have been identified in families with inclusion body myopathy, Paget disease, frontotemporal dementia, and amyotrophic lateral sclerosis, which is also referred to as multisystem proteinopathy. 57, 58 Although the histology of inclusion body myopathy in multisystem proteinopathy often lacks inflammatory infiltrates, some patients with mutations in the valosin-containing protein gene have been identified in a cohort of sIBM patients. 59 Also, familial amyotrophic lateral sclerosis-related proteins, such as TDP-43, OPTN and FUS/TLS, have been shown to accumulate in the sarcoplasm in sIBM. 60 Thus, these findings suggest a similarity in the degenerative pathomechanisms of sIBM and multisystem proteinopathy. Further investigation of the pathogenesis of multisystem proteinopathy might provide a better understanding of the degenerative pathomechanisms of sIBM. In our assays, a serum sample from a patient with GNE myopathy was examined and tested negative for the anti-cN1A autoantibody. Therefore, more samples from patients with vacuolar myopathies, such as GNE myopathy or valosin-containing protein myopathy, should be examined for the presence of the autoantibodies to realize the similarity in the pathogenesis between sIBM and hereditary vacuolar myopathies.
Relationship between the immunological and degenerative pathomechanisms
The pathogenesis of sIBM is not yet fully understood. Muscle biopsies show features associated with both immunological and degenerative pathomechanisms, but it is critical to determine which mechanism is the trigger and how the mechanisms interact. Generally, the inflammatory changes are more frequently observed early in the disease, whereas the degenerative changes are seen more often in the advanced stages of the disease. 61 It remains an enigma as to why sIBM does not respond to treatment with commonly used immunosuppressants.
Treatment
So far, no effective treatment has been established for sIBM; however, there have been relatively few randomized controlled trials. A few case reports have described transient improvements or stabilizations of muscle strength during prednisone treatment, but there has been no benefit to muscle strength in patients receiving oral prednisone. 62, 63 Instead, rimmed vacuoles and intracellular amyloid-like deposits might increase after prednisone treatment, indicating a possible noxious effect of the corticosteroid. 62 Although the use of intravenous immunoglobulin therapy is still controversial, some mild improvement has been observed in patients treated with intravenous immunoglobulin therapy. [64] [65] [66] [67] [68] [69] The benefit was more pronounced in sIBM patients with dysphagia. 65, 67 Recently, Cherin et al. 69 reported six cases of sIBM treated with subcutaneous Ig, resulting in improved muscle strength and the resolution of dysphagia.
Immunosuppressive treatments, such as the administration of methotrexate or mycophenolate mofetil, do not decelerate disease progression. 70, 71 Patients who received combination therapy comprising methotrexate and anti-T-lymphocyte globulin had increased muscle strength, compared with patients who received methotrexate alone. Thus, a randomized placebo-controlled trial would be needed to confirm the efficacy of anti-T-lymphocyte globulin. 72 Calcineurin inhibitors, such as cyclosporine A or tacrolimus, in combination with high doses of corticosteroids were used in three patients with sIBM, resulting in a complete clinical response. 73 A randomized placebo-controlled trial for the administration of interferon b-1a to patients with sIBM showed no significant differences in muscle strength or atrophy between the interferon b-1a group and the placebo group. 72 Tumor necrosis factor blocking agents, etanercept and infliximab, have been evaluated in sIBM, without obvious improvements in disease progression. 74 Of note, a long-term observational study of French and British sIBM patients suggested a possible deleterious effect of immunosuppressants with respect to rapid progression; thus, the use of immunosuppressants in sIBM must be pursued with caution. 19 An ongoing trial for treatment with bimagrumab, an inhibitor of activin type II receptors in the myostatin pathway, is evaluating changes in the distances achieved in the 6-min walk test after 52 weeks. Arimoclomol, a heat shock protein inducer, was confirmed to be safe and tolerated in sIBM patients. 75 
Conclusions
Until several years ago, sIBM was thought to be a rare disorder in Japan, compared with its prevalence in Western countries. However, recent intensive investigations have shown that the number of patients with sIBM has increased over the past 30 years, and that the prevalence in Japan is almost equal to that in Western countries. The aging of the Japanese society is expected to produce further increases in the number of patients with sIBM in Japan.
Although the pathogenesis of sIBM has been partially resolved, the essential pathomechanisms remain unknown and there is no evidence-based treatment. The discovery of anti-cN1A autoantibodies will have clinical utility for the accurate, specific diagnosis of sIBM. Furthermore, the autoantibodies might have direct pathogenic roles in the development of the disease. Further investigation of the molecular mechanisms by which the sarcoplasmic autoantigen is recognized and involved in the degeneration of myofibers will provide a better understanding of the relationship between the inflammatory and degenerative processes of sIBM.
